Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences


NEW YORK, Feb. 25, 2015 (GLOBE NEWSWIRE) — Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that corporate presentations will be delivered at the following upcoming investor conferences:

Cowen and Company 35th Annual Health Care Conference (Boston, MA)
Presenter: Greg Madison, President and Chief Operating Officer
Presentation Date: Monday, March 2nd, 2015
Presentation Time: 4:50 pm ET

27th Annual ROTH Conference (Dana Point, CA)
Presenter: Abraham Ceesay, VP, Marketing and Operations
Presentation Date: Monday, March 9th, 2015
Presentation Time: 9:00 am PT (12:00 noon ET)

Live audio webcasts of these presentations will be accessible within the Investor Relations section of the Company’s Website at An archived version of each webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company launched its first FDA-approved product, Auryxia, in the United States in December 2014. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. For more information about Keryx, please visit

CONTACT: Amy Sullivan, Vice President - Corporate Development
         and Public Affairs
         Keryx Biopharmaceuticals, Inc.
         Tel: 617.466.3447

Keryx Logo

Keryx Biopharmaceuticals, Inc.

You are leaving

You are leaving, a website of Keryx Biopharmaceuticals, Inc. Keryx does not review or control the content of non-Keryx websites, and this hyperlink does not constitute an endorsement by Keryx of the site’s content. Keryx’s privacy procedures do not apply to the owners of a non-Keryx website.